









市場行情
/
股票
/
nasdaq-qure
/

Uniqure NV

QURE

24.810USD

-0.380-1.51%

收盤 12/26, 16:00（美東）報價延遲15分鐘

1.54B總市值

虧損本益比TTM



Uniqure NV

24.810

-0.380-1.51%

概覽公司財務分析

概覽

公司

財務

分析

關於 Uniqure NV 公司

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Uniqure NV簡介



公司代碼QURE

公司名稱Uniqure NV

上市日期Feb 05, 2014

CEOKapusta (Matthew)

員工數量209

證券類型Ordinary Share

年結日Feb 05

公司地址Paasheuvelweg 25a

城市AMSTERDAM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編1105 BP

電話31202406000

網址https://www.uniqure.com/

公司代碼QURE

上市日期Feb 05, 2014

CEOKapusta (Matthew)

Uniqure NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Christian Klemt, CPA

Chief Financial Officer

99.26K

Walid Abi-Saab

Chief Medical Officer

34.63K

-4.06%

Dr. Robert Gut, M.D., Ph.D.

Non-Executive Director

32.06K

-32.72%

Mr. Madhavan (Madhu) Balachandran

Non-Executive Independent Director

29.62K

+24.66%

Dr. Jeremy P. Springhorn, Ph.D.

Non-Executive Independent Director

29.61K

+24.66%

Dr. Leonard E. Post, Ph.D.

Non-Executive Independent Director

21.86K

+36.61%

Ms. Rachelle Suzanne Jacques

Non-Executive Independent Director

20.27K

+40.66%

Dr. Jeannette Potts, J.D., Ph.D.

Chief Legal and Compliance Officer and Corporate Secretary

15.67K

-22.96%

Mr. Jack L. Kaye, CPA

Non-Executive Independent Director

Mr. David Meek

Non-Executive Independent Chairman of the Board

名稱

名稱/職務

職務

持股

持股變動

Mr. Christian Klemt, CPA

Chief Financial Officer

99.26K

Walid Abi-Saab

Chief Medical Officer

34.63K

-4.06%

Dr. Robert Gut, M.D., Ph.D.

Non-Executive Director

32.06K

-32.72%

Mr. Madhavan (Madhu) Balachandran

Non-Executive Independent Director

29.62K

+24.66%

Dr. Jeremy P. Springhorn, Ph.D.

Non-Executive Independent Director

29.61K

+24.66%

Dr. Leonard E. Post, Ph.D.

Non-Executive Independent Director

21.86K

+36.61%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月7日週日

持股股東

股東類型

持股股東

佔比

Fidelity Management & Research Company LLC

8.90%

Avoro Capital Advisors LLC

7.13%

RTW Investments L.P.

7.10%

EcoR1 Capital, LLC

6.40%

abrdn Inc.

4.72%

其他

65.73%

持股股東

佔比

Fidelity Management & Research Company LLC

8.90%

Avoro Capital Advisors LLC

7.13%

RTW Investments L.P.

7.10%

EcoR1 Capital, LLC

6.40%

abrdn Inc.

4.72%

其他

65.73%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

39.47%

Investment Advisor

26.44%

Hedge Fund

19.09%

Corporation

3.83%

Research Firm

3.16%

Individual Investor

1.48%

Venture Capital

1.48%

Pension Fund

0.92%

Private Equity

0.89%

其他

3.23%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

368

55.15M

89.53%

-7.50M

2025Q2

396

55.26M

101.06%

-1.58M

2025Q1

429

55.29M

101.00%

-4.83M

2024Q4

431

46.57M

86.23%

-10.92M

2024Q3

431

43.93M

89.29%

-10.96M

2024Q2

435

37.07M

76.08%

-15.19M

2024Q1

449

38.56M

80.27%

-17.69M

2023Q4

454

43.54M

90.77%

-8.61M

2023Q3

462

41.52M

86.64%

-16.34M

2023Q2

452

41.43M

87.10%

-18.53M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Fidelity Management & Research Company LLC

802.61K

1.3%

-47.04K

-5.54%

Jun 30, 2025

Avoro Capital Advisors LLC

3.63M

5.88%

+1.45M

+66.67%

Jun 30, 2025

RTW Investments L.P.

5.16M

8.37%

+892.80K

+20.93%

Jun 30, 2025

EcoR1 Capital, LLC

3.99M

6.48%

Jun 30, 2025

abrdn Inc.

2.75M

4.47%

+535.16K

+24.15%

Jun 30, 2025

Bristol Myers Squibb

2.39M

3.88%

Sep 30, 2024

Franklin Advisers, Inc.

1.61M

2.61%

-382.31K

-19.23%

Jun 30, 2025

State Street Investment Management (US)

1.14M

1.86%

-86.78K

-7.06%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.25M

2.03%

-53.87K

-4.12%

Jun 30, 2025

Two Sigma Investments, LP

1.60M

2.6%

+15.67K

+0.99%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Global X Genomics & Biotechnology ETF

3.77%

WisdomTree BioRevolution Fund

3.51%

Virtus LifeSci Biotech Clinical Trials ETF

2.87%

Invesco NASDAQ Future Gen 200 ETF

2.23%

Alger Mid Cap 40 ETF

2.06%

State Street SPDR S&P Biotech ETF

1.37%

Direxion Daily S&P Biotech Bull 3X Shares

0.84%

ProShares Ultra Nasdaq Biotechnology

0.36%

Invesco Nasdaq Biotechnology ETF

0.36%

Franklin Genomic Advancements ETF

0.34%

Global X Genomics & Biotechnology ETF

佔比3.77%

WisdomTree BioRevolution Fund

佔比3.51%

Virtus LifeSci Biotech Clinical Trials ETF

佔比2.87%

Invesco NASDAQ Future Gen 200 ETF

佔比2.23%

Alger Mid Cap 40 ETF

佔比2.06%

State Street SPDR S&P Biotech ETF

佔比1.37%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.84%

ProShares Ultra Nasdaq Biotechnology

佔比0.36%

Invesco Nasdaq Biotechnology ETF

佔比0.36%

Franklin Genomic Advancements ETF

佔比0.34%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Uniqure NV的前五大股東是誰？



Uniqure NV的前五大股東如下：
Fidelity Management & Research Company LLC
持有股份：802.61K
佔總股份比例：1.30%。
Avoro Capital Advisors LLC
持有股份：3.63M
佔總股份比例：5.88%。
RTW Investments L.P.
持有股份：5.16M
佔總股份比例：8.37%。
EcoR1 Capital, LLC
持有股份：3.99M
佔總股份比例：6.48%。
abrdn Inc.
持有股份：2.75M
佔總股份比例：4.47%。